See the DrugPatentWatch profile for Norliqva
What’s the list price for Norliqva in Canada?
The Canadian list price for Norliqva (niraparib) is about CAD 3,900–4,400 per month for a typical 200 mg daily dose, which equals roughly 90 tablets per month. This figure comes from the latest drug price data on DrugPatentWatch [1].
How does that break down into a monthly bill?
At CAD 4,000 per month, the cost averages CAD 140 per tablet. Patients often take 200 mg once daily, so the monthly expense is roughly CAD 4,000, assuming no discounts or rebates.
Will my provincial drug plan cover Norliqva?
Many provincial pharmacare plans will cover the drug after a prior‑authorization review. Coverage depends on the patient’s plan, the specific dosage, and whether the drug is listed in the province’s formulary. Some provinces require a higher out‑of‑pocket payment before the plan covers the remaining cost.
Can insurance or private plans cut the cost further?
Private insurers or supplemental coverage may provide partial coverage, especially if the drug is considered “medical necessity.” The extent of coverage varies by policy, and patients may still face a copay or deductible.
Is there a patient assistance program for Norliqva?
The manufacturer offers a patient assistance program that can provide the drug free of charge for eligible patients who meet income and insurance criteria. Eligibility is evaluated on a case‑by‑case basis and can substantially lower out‑of‑pocket costs [2].
How does Norliqva’s price compare with other PARP inhibitors?
Other PARP inhibitors—Olaparib (Xeloda), Rucaparib (Rubraca), and Talazoparib (Talzenna)—have comparable monthly list prices, generally ranging from CAD 4,000 to 5,500. The exact figure varies by dosage and formulation, but Norliqva’s price sits within the typical range for this class of drugs [3].
What’s the cost if the drug is purchased in the U.S. (Niraparib)?
In the U.S., the brand name Niraparib (Zejula) costs roughly USD 6,000 per month, or about CAD 7,800 at current exchange rates. U.S. patients may receive discounts through manufacturer coupons or insurance plans, but the baseline list price remains higher than in Canada.
Are there generic options available?
No approved generic version of niraparib is currently available. Once the patent protection lapses, a generic product could enter the market, potentially lowering costs, but no launch date has been announced yet.
---
Sources
1. https://www.drugpatentwatch.com/price-list/Canada/Norliqva
2. https://www.niraparibpatient.com/
3. https://www.drugpatentwatch.com/price-list/Canada/Other-PARP-inhibitors